

### Devyani Chowdhury, MBBS, FACC

Director of Cardiology Care for Children; Medical Director of ACHD at
Nemour's c
Cardiology Care For Children

Printed as of 7/18/2024

# **Disclosures**

## Personal Commercial (2)

| Company Name  | Relationship Category | Compensation Level | Topic Area(s)                      |
|---|-----------------------|--------------------|------------------------------------|
| Self  |                       |                    |                                    |
| National Institute of Health Research/Research Grants |                       | Modest (< \$5,000) | Other                              |
| Tenaya Pharmaceuticals Consultant Fees/Honoraria      |                       | None (\$0)         | Heart Failure and Cardiomyopathies |

# Additional Personal Commercial Disclosures for Education Activities (1)

| Company Name | any Name Relationship Category |            | Topic Area(s)      |
|--------------|--------------------------------|------------|--------------------|
| Self         |                                |            |                    |
| TELERAY      | Other - Advisory Board         | None (\$0) | General Cardiology |

### Personal Organizational or Other Non-Commercial (1)

| Non-Commercial Enity Name         | Relationship Category    | Compensation Level | Topic Area(s)                                     |
|-----------------------------------|--------------------------|--------------------|---|
| Self                              |                          |                    |   |
| Bill and Melinda Gates Foundation | Research/Research Grants | None (\$0)         | Congenital Heart Disease and Pediatric Cardiology |

### Clinical Trial Enroller (0)

No disclosures on record

## Institutional Financial Decision-Making Role (0)

No disclosures on record

# **Expert Witness Testimony (1)**

| Year | Case Title                     | Represented | Description | Compensation       |
|------|--------------------------------|-------------|-------------|--------------------|
| Self |                                |             |             |                    |
| 2020 | Pulmonary hypertension and PDA | Plaintiff   |             | Modest (< \$5,000) |

† Commercial Funding Source | ‡ Trial Name

# **Agreement**

## Certified Education Attestation | Signed on 10/17/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement (Continuous) and the properties of the pro

## Confidentiality, Disclosure and Assignment Agreement | Signed on 10/17/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

**Embargo** | Signed on 10/17/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 2/27/2024

#### **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.